A Phase I, open-label, parallel-group study to investigate the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single subcutaneous administration of RO7434656 in healthy adult Chinese participants
Latest Information Update: 04 Sep 2024
At a glance
- Drugs IONIS FB LRX (Primary)
- Indications IgA nephropathy
- Focus Pharmacokinetics
- Sponsors Roche
Most Recent Events
- 04 Sep 2024 Status changed from not yet recruiting to recruiting.
- 27 Aug 2024 New trial record